

AKEEGA
(niraparib and abiraterone acetate)

Pre - PA Allowance

None

Prior-Approval Requirements

Age 18 years of age or older

Diagnosis

Patient must have the following:

Metastatic castration-resistant prostate cancer (mCRPC)

AND ALL of the following:

1. Deleterious or suspected deleterious *BRCA* mutation
2. Used in combination with prednisone
3. Patient has had a bilateral orchiectomy **OR** patient will be receiving a gonadotropin-releasing hormone (GnRH) analog concurrently
4. Prescriber agrees to obtain a complete blood count (CBC) at baseline, weekly for the first month, and monthly thereafter
5. Prescriber agrees to monitor for cardiovascular effects
6. **NO** dual therapy with another androgen receptor inhibitor (see Appendix 1)
7. Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment and for 4 months after the last dose

Prior - Approval Limits

Quantity 180 tablets per 90 days

Duration 12 months

Prior – Approval *Renewal* Requirements

Age 18 years of age or older

Diagnosis

Patient must have the following:

Metastatic castration-resistant prostate cancer (mCRPC)

**AKEEGA
(niraparib and abiraterone acetate)**

AND ALL of the following:

1. Used in combination with prednisone
2. Prescriber agrees to obtain complete blood counts (CBCs) as clinically indicated
3. Prescriber agrees to monitor for cardiovascular effects
4. **NO** disease progression or unacceptable toxicity
5. **NO** dual therapy with an androgen receptor inhibitor (see Appendix 1)
6. Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment and for 4 months after the last dose

Prior - Approval *Renewal* Limits

Same as above

Appendix 1 - List of Androgen Receptor Inhibitors

Generic Name	Brand Name
abiraterone	Yonsa
abiraterone	Zytiga
abiraterone/niraparib	Akeega
apalutamide	Erleada
darolutamide	Nubeqa
enzalutamide	Xtandi
nilutamide	Nilandron